Intercos (BIT:ICOS)
Historical Stock Chart
From May 2019 to May 2024
New BASS Sponsor Cialis(R) (tadalafil) Showcases Interactive
Presence in Augusta
-- Cialis Boat, Truck and Relaxation Tent Headline On-Site Activities --
AUGUSTA, Ga., March 2 /PRNewswire-FirstCall/ -- Cialis(R) (tadalafil), the
erectile dysfunction drug marketed by Lilly ICOS
(NYSE:LLYNYSE:andNYSE:Nasdaq:NYSE:ICOS), is unveiling its full sponsorship
program today at the Bassmaster Tournament Trail event being held at the J.
Strom Thurmond Reservoir. The Cialis-branded boat made an auspicious debut at
the season-opener in Kissimmee, Fla. when Takahiro Omori, the defending CITGO
Bassmaster Classic champion, chose the Cialis bass boat on the final two days
of competition to claim victory and the $100,000 winner's purse.
Fans on-site at the reservoir can experience the various innovative elements as
part of the premiere sponsorship by Cialis:
* Exhibition Tent: Spectators in Augusta can experience the "Bassmaster
University presented by Cialis" tent, which will be stocked with interactive
fishing-related activities and seminars with expert anglers. Highlights from
ESPN2's Bassmaster University show will also be featured in the Cialis tent.
* Relaxation Center: One designated area in front of the weigh-in will be
branded "Relaxation Center presented by Cialis." The relaxing atmosphere will
be designed to help spectators unwind and enjoy close-up views of the weigh-in.
Cialis will have a strong signage presence at the event, including boat, truck
and driver uniform signage.
"During this exciting Bassmaster Tournament Trail event, we hope that fans and
anglers will experience the on-site activities that were designed to help
enhance relaxation and enjoyment of the sport of bass fishing," said Matt
Beebe, Cialis U.S. Brand Team Leader. "BASS members are an important audience
to us. Our alliance with BASS allows us to reach a targeted fan base that
enjoys bass fishing because it's both relaxing and exhilarating."
For those fans watching from home, Cialis is involved in the action via
television and the Web site:
* Bassmaster University: Cialis is the presenting sponsor of Bassmaster
University for the entire 2005 season. This includes opening and closing
credits on each episode as well as a weekly "Cialis Angler's Ready List" that
highlights fishing equipment needed for each lesson. An online Bassmaster
University page will link to http://www.cialis.com/ . Bassmaster University
airs on BASS Saturday at 9:30 a.m. ET/PT and 8:30 a.m. CT on ESPN2.
* Interactive Web Site: Angling fans everywhere can soon visit
http://www.bassmaster.com/ to experience many of the innovative elements of the
Cialis BASS sponsorship, including tips for relaxing and improving their
fishing skills.
Cialis BASS Sponsorship
As part of the one-year agreement, Cialis will have a major interactive
presence at the majority of BASS events, including the CITGO Bassmaster Tour,
the Bassmaster Elite 50 Series and the CITGO Bassmaster Classic.
For Lilly ICOS, the BASS sponsorship represents a unique opportunity to educate
men in the United States about a significant health issue -- erectile
dysfunction (ED) -- and the role of Cialis as the only oral ED treatment shown
to improve erectile function for up to 36 hours in most men. Through its
partnership with BASS, Lilly ICOS offers consumers information about ED and
Cialis. Consumers may pick up brochures on ED or Cialis at the tents, and
visit the Cialis Web site, http://www.cialis.com/ , to get more information
about Cialis. Available by prescription, Cialis was approved by the U.S. Food
& Drug Administration on November 21, 2003.
About BASS
BASS is the world's largest fishing organization, sanctioning more than 20,000
tournaments worldwide through its Federation. The CITGO Bassmaster Tournament
Trail, which includes the exciting Bassmaster Elite 50 series, is the oldest
and most prestigious pro bass fishing tournament circuit and continues to set
the standard for credibility, professionalism and sportsmanship as it has since
1968. For more information, contact BASS Communications at (334) 551-2375 or
visit http://www.bassmaster.com/ .
About Cialis
Cialis, approved by the FDA in November 2003 for the treatment of erectile
dysfunction, is the only oral ED treatment shown to improve erectile function
up to 36 hours in most men. Cialis can be taken without regard to food. The
absorption of Cialis is not reduced by food, including high-fat foods. Cialis
is currently available in approximately 100 countries, including Australia,
Brazil, Mexico, Canada, the United States and countries throughout Europe. More
than 3.5 million patients worldwide have been treated with Cialis since its
first introduction in February 2003.
Cialis is available by prescription only and is not for everyone. Men taking
nitrates, often used for chest pain, or certain alpha-blockers for prostate
problems or high blood pressure, should not take Cialis. Such combinations
could cause a sudden, unsafe drop in blood pressure.
Men should discuss their health status with their doctors to ensure Cialis is
right for them and that they are healthy enough for sexual activity. The most
common side effects with Cialis were headache, upset stomach, delayed backache
or muscle ache. Although rare, men who experience an erection for more than
four hours should seek immediate medical attention. Men should not drink
alcohol in excess with Cialis. Cialis does not protect a man or his partner
from sexually transmitted diseases, including HIV.
Individual results may vary. Cialis studies were not designed to assess
multiple intercourse attempts after a single dose. For full patient
information, visit http://www.cialis.com/ .
About Lilly ICOS LLC
Lilly ICOS LLC, a joint venture between ICOS Corporation (NASDAQ:ICOS) and Eli
Lilly and Company (NYSE:LLY), developed tadalafil for the treatment of erectile
dysfunction.
ICOS Corporation, a biotechnology company headquartered in Bothell, Washington,
is dedicated to bringing innovative therapeutics to patients. ICOS is marketing
its product, Cialis (tadalafil), through Lilly ICOS LLC. ICOS is working to
develop treatments for serious unmet medical conditions such as chronic
obstructive pulmonary disease, benign prostatic hyperplasia, cancer and
inflammatory diseases.
Lilly, a leading innovation-driven corporation is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and information
-- for some of the world's most urgent medical needs. Additional information
about Lilly is available at http://www.lilly.com/ .
P-LLY
Except for historical information contained herein, this press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements are based on
current expectations, estimates and projections about the industry, management
beliefs and certain assumptions made by the management of ICOS and Lilly.
Investors are cautioned that matters subject to forward-looking statements
involve risks and uncertainties, including economic, competitive, governmental,
technological, legal and other factors discussed in the two companies'
respective filings with the Securities and Exchange Commission, which may
affect the business and prospects of the two companies and Lilly ICOS. Results
and the timing and outcome of events may differ materially from those expressed
or implied by the forward-looking statements in this press release. More
specifically, there can be no assurance that Cialis will achieve commercial
success or that competing products will not pre-empt market opportunities that
might exist for the product.
Cialis(R) is a registered trademark of Lilly ICOS LLC. Other trademarks are
the property of their respective owners.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO )
http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO
DATASOURCE: Lilly ICOS LLC
CONTACT: Kindra Strupp of Lilly ICOS, +1-317-277-5170; or Jamie
Wilkinson of BASS, +1-334-551-2457